96O Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (T) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2+ breast cancer: Subgroup analysis from KATHERINE
Titel:
96O Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (T) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2+ breast cancer: Subgroup analysis from KATHERINE
Auteur:
Loibl, S. Huang, C-S. Mano, M.S. Mamounas, T.P. Geyer, C.E. Untch, M. von Minckwitz, G. Thery, J-C. Schwaner, I. Limentani, S. Loman, N. Lübbe, K. Chang, J.C. Hatschek, T. Tesarowski, D. Boulet, T. Wiese, C. Song, C. Wolmark, N.